Open AccessRandomized Study of Maintenance Vinorelbine in Responders With Advanced Non-Small-Cell Lung Cancer
Author(s) -
Virginie Westeel,
Élisabeth Quoix,
D. MoroSibilot,
Mariette Mercier,
Jean-Luc Breton,
D. Debieuvre,
Patrick Richard,
M.A. Haller,
B. Milleron,
D. Herman,
M C Level,
FrançoisXavier Lebas,
Marc Puyraveau,
A Depierre
Publication year - 2005
Publication title -
journal of the national cancer institute
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 5.797
H-Index - 356
eISSN - 1460-2105
pISSN - 0027-8874
DOI - 10.1093/jnci/dji096
Subject(s) - vinorelbine , medicine , regimen , ifosfamide , lung cancer , hazard ratio , maintenance therapy , induction chemotherapy , chemotherapy , oncology , surgery , stage (stratigraphy) , cisplatin , confidence interval , paleontology , biology
Prolongation of chemotherapy duration, usually referred to as maintenance chemotherapy, has been considered as an approach to improve survival of patients with advanced non-small-cell lung cancer (NSCLC). If the maintenance regimen differs from the induction regimen, patients will receive not only higher total doses of chemotherapy but also earlier delivery of non-cross-resistant agents. We conducted a randomized trial to compare maintenance vinorelbine therapy with observation in previously untreated patients who responded to induction treatment with mitomycin-ifosfamide-cisplatin (MIC).